Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis
https://doi.org/10.14412/1996-7012-2020-3-45-49
Abstract
Renal AA amyloidosis is the most severe type of renal pathology in patients with ankylosing spondylitis (AS). The characteristic symptoms of AA amyloidosis in rheumatic diseases do not often occur for years, making it difficult to diagnose it early and to start adequate therapy.
Objective: to identify the clinical features of AS complicated by secondary AA amyloidosis.
Patients and methods. The investigation enrolled 9 patients with AS (according to the 1984 modified New York criteria) and histologically confirmed secondary AA amyloidosis (Group 1). A comparison group included 216 AS patients without amyloidosis (Group 2).
Results and discussion. In Group 1 patients, the age at the onset of AS was significantly less and the disease duration was 4 times longer than those in Group 2. All the patients with AA amyloidosis had enthesitis and arthritis, including those of the hip joints. The scores of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), and the acute phase inflammation index CRP were higher in Group 1 than in Group 2.
Conclusion. The clinical feature of AS complicated by secondary AA-amyloidosis is the long duration of the disease and the high frequency of juvenile onset, non-axial manifestations (arthritis, coxitis and enteritis), as well as the high activity of systemic inflammation.
Supporting agencies: The investigation has been conducted within the framework of the exploratory topic «Development of treatments for refractory, severe ankylosing spondylitis» (R&D AAAA-A20-120041390035-8).
About the Authors
D. G. Rumyantseva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Daria Gavrilyevna Rumyantseva
34A, Kashirskoe Shosse, Moscow 115522
E. M. Agafonova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
S. O. Krasnenko
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. S. Starkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. M. Urumova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Sh. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(6): 657-60. (In Russ.). doi: 10.14412/19954484-2015-657-660
2. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: Review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524-30. doi: 10.1007/BF01451293.
3. Shavlovskii MM. Molecular and genetic basis of the pathogenesis of the amyloidoses. Meditsinskii akademicheskii zhurnal 2010; 10(4):63-81. (In Russ.).
4. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016 Dec;23(4):209-13. doi: 10.1080/13506129.2016.1257986. Epub 2016 Nov 24.
5. Molto A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016 Jun;75(6):1016-23. doi: 10.1136/annrheumdis-2015-208174. Epub 2015 Oct 21.
6. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999 Apr;37(4):381-8. doi: 10.1515/CCLM.1999.063.
7. Hagihara K, Nishikawa T, Isobe T, et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004 Feb 6; 314(2):363-9. doi: 10.1016/j.bbrc.2003.12.096.
8. Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019 Mar;29(2):268-74. doi: 10.1080/14397595.2018.1515145. Epub 2018 Oct 2.
9. Fernandez-Nebro A, Olive A, Castro MC, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010 May;123(5):454-61. doi: 10.1016/j.amjmed.2009.11.010.
10. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006 Sep;54(9): 2997-3000. doi: 10.1002/art.22118.
11. Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated lifethreatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009 Sep;28(9):1113-6. doi: 10.1007/s10067-009-1185-0. Epub 2009 May 13..
12. Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011 Dec;18(4):235-9. doi: 10.3109/13506129.2011.613962. Epub 2011 Oct 12.
13. Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid A deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010 Oct;29(10):1195-7. doi: 10.1007/s10067-010-1422-6. Epub 2010 Mar 15.
14. Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009 Jul; 68(7):1235-6. doi: 10.1136/ard.2008.099267.
15. Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011 Apr;21(2): 215-8. doi: 10.1007/s10165-010-0365-8. Epub 2010 Oct 8.
16. Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 Jan;24(1):137-43. doi: 10.3109/14397595.2013.854048.
17. Hunter J, McGregor L. Do inflammatory rheumatic diseases still cause as much harm through amyloidosis? Amyloid. 2011 Jun;18 Suppl 1:208-10. doi: 10.3109/13506129.2011.574354078.
18. Podryadnova MV, Balabanova RM, Urumova MM, Erdes ShF. Correlation between clinical characteristics of ankylosing spondylitis and work capacity and productivity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014; 52(5):513-9. (In Russ.). doi: 10.14412/19954484-2014-513-519
19. Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):344-50. (In Russ.). doi: 10.14412/1995-4484-2017-344-350
20. Villiaumey J, Lejeune E, Avouac B, Horreard P. Spondylarthrite ankylosante et amylose. Ann Med Interne (Paris). 1978 Jan; 129(1):67-71.
21. Cristoph R, Genth E, Hartl W. Incidence of amyloidosis in ankylosing spondylitis. Scand J Rheumatol. 1975;8:39.
22. Okuda Y, Yamada T, Matsuura M, et al. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011 Sep; 18(3):108-11. doi: 10.3109/13506129.2011.582198. Epub 2011 Jun 1.
23. Hsu HC, Zhou T, Yang PA, et al. Increased acute-phase response and renal amyloidosis in aged CD2-fastransgenic mice. J Immunol. 1997 Jun 15;158(12):5988-96.
24. Barbouch S, Hajji M, Jaziri F, et al. Renal amyloidosis in ankylosing spondylitis: a monocentric study and review of literature. Saudi J Kidney Dis Transpl. Mar-Apr 2018; 29(2):386-91. doi: 10.4103/1319-2442.229291.
25. Hajjaj-Hassouni N, Laghrissi S, Khalil A, et al. Ankylosing spondylitis and amyloidosis. Apropos of 2 cases. Rev Rhum Mal Osteoartic. 1982 Oct;49(10):687-91.
26. Lance NJ, Curran JJ. Amyloidosis in a case of ankylosing spondylitis with a review of the literature. J Rheumatol. 1991 Jan; 18(1):100-3.
27. Gomez-Casanovas E., Sanmarti R., Sole M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001 Jan;44(1):66-72. doi: 10.1002/15290131(200101)44:1<66::AID-ANR10>3.0.CO;2-H.
28. Murav'ev YuV, Radenska-Lapovok SG, Alekseeva AV, et al. Unusual course of AA amiloidosis in a patient with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(2):73-5. (In Russ.). doi: 10.14412/1995-4484-2009-462
Review
For citations:
Rumyantseva DG, Agafonova EM, Krasnenko SO, Starkova AS, Urumova MM, Erdes S. Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(3):45-49. (In Russ.) https://doi.org/10.14412/1996-7012-2020-3-45-49
Views:
881
Email this article 